Last reviewed · How we verify

Collagenase Clostridium Histolyticum-Aaes

Luxurgery · FDA-approved active Small molecule

Collagenase Clostridium Histolyticum-Aaes is a bacterial enzyme that directly breaks down collagen in connective tissue, allowing mechanical disruption of fibrotic structures.

Collagenase Clostridium Histolyticum-Aaes is a bacterial enzyme that directly breaks down collagen in connective tissue, allowing mechanical disruption of fibrotic structures. Used for Dupuytren's contracture, Peyronie's disease.

At a glance

Generic nameCollagenase Clostridium Histolyticum-Aaes
Also known asQWO
SponsorLuxurgery
Drug classCollagenase enzyme
TargetCollagen types I and III
ModalitySmall molecule
Therapeutic areaDermatology / Rheumatology
PhaseFDA-approved

Mechanism of action

This enzyme cleaves collagen types I and III at specific peptide bonds, degrading the structural protein that forms the basis of fibrotic cords and contractures. By enzymatically weakening the collagen matrix, the drug enables subsequent mechanical manipulation or natural remodeling of the affected tissue. This mechanism is particularly useful in conditions where abnormal collagen deposition creates mechanical contractures or fibrotic bands.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: